Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials
- 562 Downloads
The interest in platinum salts in breast cancer (BC) therapy has been recently renewed as inhibition of DNA damage response may enhance the effects of DNA-damaging agents in BC tumors with high genomic instability. The present systematic review and meta-analysis of randomized trials were performed to assess the efficacy and safety of therapy with platinum salts in patients with locally advanced or metastatic (hereinafter advanced) BC.
We searched PubMed, EMBASE, SCOPUS, Web of Science, the Cochrane Library, and CINAHL for phase II/III clinical trials that assessed efficacy of platinum-based therapy in patients with advanced BC. Pooled estimates of overall response rate (RR), median progression-free survival (PFS) and overall survival (OS) were computed using random or fixed effects models.
Data on 4625 patients from 23 phase II and III trials (11 with cisplatin, 11 with carboplatin, and 1 with either agents respectively) were analyzed. Estimates for RR, PFS, and OS were obtained from 23, 13, and 15 studies, respectively. Although at the cost of significantly increased fatigue, hematological and gastrointestinal toxicity, compared with non-platinum schemas, cisplatin, and carboplatin prolonged OS (HR 0.91; 95 % CI 0.83–1.00, p = 0.04), PFS (HR 0.84; 95 % CI 0.73–0.97, p = 0.01), and RR (HR 1.27; 95 % CI 1.03–1.57, p = 0.03).
Despite some limitations of the studies examined, including partial information on hormonal receptor and HER2 status, the use of platinum salts significantly prolonged OS, and PFS of patients with advanced BC with no unexpected toxicity.
KeywordsAdvanced breast cancer Cisplatinum Carboplatinum Meta-analysis Survival
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 4.Carrick S, Ghersi D, Wilcken N, Simes J (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD003374.pub3
- 5.Hu XC, Zhang J, Xu BH et al (2015) Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16:436–446. doi: 10.1016/S1470-2045(15)70064-1 CrossRefPubMedGoogle Scholar
- 7.Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y (2014) Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat 145:401–409CrossRefPubMedGoogle Scholar
- 8.Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284CrossRefPubMedGoogle Scholar
- 9.Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Deeks JJ, Higgins JP, Altman DG (2011) Analysing data and undertaking meta-analyses. In: Higgins JP, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, ChichesterGoogle Scholar
- 17.Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, Passalacqua R, Tonato M (1991) Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 9:664–669PubMedGoogle Scholar
- 18.Cocconi G, Bisagni G, Ceci G, Di Blasio B, De Lisi V, Passalacqua R, Zadro A, Boni C, Morandi P, Savoldi L (1999) Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial. Breast Cancer Res Treat 56:125–132CrossRefPubMedGoogle Scholar
- 19.Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E, McIntyre OR, Schilsky RL (1999) Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study—Cancer and Leukemia Group B 8642. J Clin Oncol 17:1397–1406PubMedGoogle Scholar
- 20.Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT, Walsh G, Ashley S (1998) Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 16:1350–1357PubMedGoogle Scholar
- 21.Icli F, Akbulut H, Uner A et al (2005) Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomized phase III trial of Turkish Oncology Group. Br J Cancer 92:639–644. doi: 10.1038/sj.bjc.6602388 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Berruti A, Bitossi R, Gorzegno G et al (2002) Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol 20:4150–4159. doi: 10.1200/JCO.2002.08.012 CrossRefPubMedGoogle Scholar
- 23.Fountzilas G, Kalofonos HP, Dafni U et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517–1526. doi: 10.1093/annonc/mdh395 CrossRefPubMedGoogle Scholar
- 26.Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786–2792. doi: 10.1200/JCO.2005.04.1764 CrossRefPubMedGoogle Scholar
- 27.Frasci G, D’Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G (2006) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer 95:1005–1012. doi: 10.1038/sj.bjc.6603395 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Xu B, Jiang Z, Kim SB, Yu S, Feng J, Malzyner A, del Giglio A, Chung HC, Shen LJ, Pen DLK (2011) Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer 18:203–212. doi: 10.1007/s12282-011-0260-y CrossRefPubMedGoogle Scholar
- 30.Stemmler HJ, diGioia D, Freier W, Tessen HW, Gitsch G, Jonat W, Brugger W, Kettner E, Abenhardt W, Tesch H, Hurtz HJ, Rosel S, Brudler O, Heinemann V (2011) Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer 104:1071–1078. doi: 10.1038/bjc.2011.86 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156. doi: 10.1200/JCO.2010.28.6450 CrossRefPubMedGoogle Scholar
- 32.Huang L, Chen S, Yang W et al (2015) Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II–III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget 6:18683–18692CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N (2013) Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD008792.pub2